pHion Therapeutics is a UK based biotech delivering ground-breaking nucleic acid vaccines and therapeutics. The proprietary RALA peptide-based drug delivery system is based on a sequence of 30 amino acids which condenses anionic cargo (RNA and DNA), irrespective of size, into nanoparticles. These nanoparticles are highly efficient at cellular entry with 100% release from the endosomes. When used in vaccines, the RALA platform can deliver multiple anionic molecules, such as mRNA, in a stealth-like way by evading detection. This generates both a potent antigen-specific CD8+ T-cell response that is ideal for therapeutic vaccines, and a long-term T-Cell and antibody memory that is ideal for prophylactic vaccines. The platform has the added advantage of ease of scalability, using globally available mixing devices, options for lyophilised or liquid formulations, no use of solvents which results in a more sustainable product, and reduced wastage with >99% encapsulation of cargo. pHion's lead product is a therapeutic vaccine against HPV driven cancers (PTX_V1), with Phase I/IIA clinical trials planned to commence in 2024.pHion's pipeline programs also include therapeutic vaccines against ovarian cancer (PTX_V5), prostate cancer (PTX _V3), and a prophylactic vaccine against Crimean-Congo Haemorrhagic Fever. The company is headquartered in Belfast, Northern Ireland. invoX Pharma, an integrated global biopharmaceutical company with a diversified pipeline, is the majority shareholder of pHion Therapeutics. To learn more about invoX, visit: www.invoxpharma.com